Serum CCL20 Level in Patients with Vitiligo | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 140, Volume 85, Issue 1, October 2021, Page 3467-3473 PDF (439.3 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2021.199603 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Shimaa Mohsen Elbeah  ; Marwa Zohdy Moubarak; Fawzia Amin Saafan; Amany Saleh Khalil
| ||||
| Abstract | ||||
| Background: Vitiligo is a chronic, acquired depigmenting cutaneous disorder due to damage of melanocytes in genetically susceptible persons. The existence of vitiligo is mediated by the autoimmune dysfunction of cases. CCL20 was expressed at low levels in normal human skin, because both CCL20 and CCR6 were significantly up-regulated within chronic inflammatory cutaneous disorders.CCL20 interacts with its receptor CCR6 to recruit IL-17A-forming cells into skin. Objective: This study was aimed to assess relationship between serum level of CCL20 in cases with vitiligo and its correlation to disease severity and activity Patients and methods: This case-control study included a total of fifty cases with vitiligo and 30 matched age and sex control attending at the outpatient clinic of Dermatology, Mansoura University Hospital. Results: CCL20 levels were considerably greater within vitiligo cases when compared to controls. CCL20 levels were found to be considerably higher in active vitiligo cases in comparison to stable vitiligo cases. Conclusion: It could be concluded that the serum level of CCL20 was demonstrated to be correlated positively with vitiligo-affected patients. Additionally, it seems to have a positive association with disease activity but not with disorder duration so CCL20 could be a candidate as a biomarker to evaluate the activity of vitiligo as well as it is a good predictor of vitiligo and discriminates patients from control. | ||||
| Keywords | ||||
| vitiligo; CCL20; melanocytes; VETF; skin | ||||
|
Statistics Article View: 232 PDF Download: 274 |
||||
